804 related articles for article (PubMed ID: 19376735)
1. Quantitative structure-activity relationships for a series of inhibitors of cruzain from Trypanosoma cruzi: molecular modeling, CoMFA and CoMSIA studies.
Trossini GH; Guido RV; Oliva G; Ferreira EI; Andricopulo AD
J Mol Graph Model; 2009 Aug; 28(1):3-11. PubMed ID: 19376735
[TBL] [Abstract][Full Text] [Related]
2. Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.
Choe Y; Brinen LS; Price MS; Engel JC; Lange M; Grisostomi C; Weston SG; Pallai PV; Cheng H; Hardy LW; Hartsough DS; McMakin M; Tilton RF; Baldino CM; Craik CS
Bioorg Med Chem; 2005 Mar; 13(6):2141-56. PubMed ID: 15727867
[TBL] [Abstract][Full Text] [Related]
3. Molecular modeling and structure-activity relationships for a series of benzimidazole derivatives as cruzain inhibitors.
Pauli I; Ferreira LG; de Souza ML; Oliva G; Ferreira RS; Dessoy MA; Slafer BW; Dias LC; Andricopulo AD
Future Med Chem; 2017 May; 9(7):641-657. PubMed ID: 28509592
[TBL] [Abstract][Full Text] [Related]
4. 2D QSAR and similarity studies on cruzain inhibitors aimed at improving selectivity over cathepsin L.
Freitas RF; Oprea TI; Montanari CA
Bioorg Med Chem; 2008 Jan; 16(2):838-53. PubMed ID: 17996450
[TBL] [Abstract][Full Text] [Related]
5. Two- and three-dimensional quantitative structure-activity relationships for a series of purine nucleoside phosphorylase inhibitors.
Castilho MS; Postigo MP; de Paula CB; Montanari CA; Oliva G; Andricopulo AD
Bioorg Med Chem; 2006 Jan; 14(2):516-27. PubMed ID: 16203153
[TBL] [Abstract][Full Text] [Related]
6. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
7. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
8. Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function.
Schormann N; Senkovich O; Walker K; Wright DL; Anderson AC; Rosowsky A; Ananthan S; Shinkre B; Velu S; Chattopadhyay D
Proteins; 2008 Dec; 73(4):889-901. PubMed ID: 18536013
[TBL] [Abstract][Full Text] [Related]
9. Cruzain inhibition by hydroxymethylnitrofurazone and nitrofurazone: investigation of a new target in Trypanosoma cruzi.
Trossini GH; Malvezzi A; T-do Amaral A; Rangel-Yagui CO; Izidoro MA; Cezari MH; Juliano L; Chin CM; Menezes CM; Ferreira EI
J Enzyme Inhib Med Chem; 2010 Feb; 25(1):62-7. PubMed ID: 20030510
[TBL] [Abstract][Full Text] [Related]
10. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
Pandey G; Saxena AK
J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
[TBL] [Abstract][Full Text] [Related]
11. CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists.
Doddareddy MR; Cho YS; Koh HY; Pae AN
Bioorg Med Chem; 2004 Aug; 12(15):3977-85. PubMed ID: 15246074
[TBL] [Abstract][Full Text] [Related]
12. 3D-QSAR and docking studies of aldehyde inhibitors of human cathepsin K.
Pan X; Tan N; Zeng G; Han H; Huang H
Bioorg Med Chem; 2006 Apr; 14(8):2771-8. PubMed ID: 16377193
[TBL] [Abstract][Full Text] [Related]
13. Three-dimensional quantitative structure-activity relationship (3D-QSAR) analyses of choline acetyltransferase inhibitors.
Chandrasekaran V; McGaughey GB; Cavallito CJ; Bowen JP
J Mol Graph Model; 2004 Sep; 23(1):69-76. PubMed ID: 15331055
[TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
[TBL] [Abstract][Full Text] [Related]
15. Molecular docking and 3D-QSAR studies of Yersinia protein tyrosine phosphatase YopH inhibitors.
Hu X; Stebbins CE
Bioorg Med Chem; 2005 Feb; 13(4):1101-9. PubMed ID: 15670918
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships for a class of selective inhibitors of the major cysteine protease from Trypanosoma cruzi.
Guido RV; Trossini GH; Castilho MS; Oliva G; Ferreira EI; Andricopulo AD
J Enzyme Inhib Med Chem; 2008 Dec; 23(6):964-73. PubMed ID: 19005945
[TBL] [Abstract][Full Text] [Related]
17. Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses.
Guo Y; Xiao J; Guo Z; Chu F; Cheng Y; Wu S
Bioorg Med Chem; 2005 Sep; 13(18):5424-34. PubMed ID: 15963726
[TBL] [Abstract][Full Text] [Related]
18. Structural investigation of PAP derivatives by CoMFA and CoMSIA reveals novel insight towards inhibition of Bcr-Abl oncoprotein.
San Juan AA
J Mol Graph Model; 2007 Sep; 26(2):482-93. PubMed ID: 17446106
[TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.
da Cunha EF; Sippl W; de Castro Ramalho T; Ceva Antunes OA; de Alencastro RB; Albuquerque MG
Eur J Med Chem; 2009 Nov; 44(11):4344-52. PubMed ID: 19616874
[TBL] [Abstract][Full Text] [Related]
20. CoMFA and CoMSIA studies on HIV-1 attachment inhibitors.
Lu P; Wei X; Zhang R
Eur J Med Chem; 2010 May; 45(5):1792-8. PubMed ID: 20149491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
